On Tuesday, RBC Capital maintained its positive stance on Viridian Therapeutics (NASDAQ:VRDN), reiterating an Outperform rating with a $35.00 price target. The firm's outlook follows Viridian's announcement of initiating two Phase III studies for its drug candidate VRDN-003 in August. These studies, named REVEAL-1 and REVEAL-2, will target active and chronic Thyroid Eye Disease (TED) patients, respectively, with results expected in the first half of 2026.
REVEAL-1 is set to enroll approximately 84 active TED patients, while REVEAL-2 aims for about 126 chronic TED patients. Should the data prove favorable, Viridian anticipates submitting a Biologics License Application (BLA) for VRDN-003 by the end of 2026. This development is seen as a positive step, aligning with insights from the Type C meeting minutes previously reviewed.
The dosing regimen for both studies will consist of a 600mg loading dose, followed by an evaluation of two different maintenance dosing schedules. The firm highlights the potential administrative advantage of VRDN-003 over Tepezza, which requires eight infusions. Viridian's strategy includes leveraging the Ypsomed autoinjector to deliver a concentrated 2mL dose via an autoinjector pen, potentially positioning VRDN-003 as a leading therapy in its class for subcutaneous administration.
RBC Capital's outlook is also buoyed by the upcoming Phase III readouts from another of Viridian's drug candidates, VRDN-001, for active TED in September and for chronic TED by the end of the year. The firm's continued support for Viridian is reflected in the maintained price target and speculative risk rating, anticipating progress in the company's development pipeline.
In other recent news, Viridian Therapeutics has made significant strides in its clinical trials. The company has completed enrollment for its Phase 3 trial of VRDN-001, a program for active thyroid eye disease (TED), with top-line results expected in September 2024. A Biologics License Application (BLA) for this program is planned for the second half of 2025. Additionally, Viridian is making progress with its subcutaneous VRDN-003 program, which is set to enter pivotal trials mid-year, following a positive Type C meeting with the FDA.
In terms of financial analysis, Wolfe Research has initiated coverage on Viridian Therapeutics with an Outperform rating, projecting a potential revenue of approximately $690 million worldwide by 2027 from the company's lead drug candidate, VRDN-001. The research firm also anticipates that Viridian could reach free cash flow positivity by 2028. Goldman Sachs has also initiated coverage on Viridian with a Buy rating, highlighting the potential of the company's leading assets, VRDN-001 and VRDN-003.
These recent developments underscore the potential financial and therapeutic impact of Viridian's lead drug candidates in the coming years. As the market looks forward to the possible success of VRDN-001 and VRDN-003, investor attention will likely be focused on the milestones and financial performance outlined by both Wolfe Research and Goldman Sachs.
InvestingPro Insights
As Viridian Therapeutics (NASDAQ:VRDN) advances its Phase III studies for VRDN-003, investors and analysts are closely monitoring the company's financial health and market performance. According to InvestingPro data, Viridian holds a market capitalization of $810.55 million, with a notably high negative price-to-earnings (P/E) ratio of -2.83. This reflects the company's current lack of profitability, a sentiment echoed by analysts who do not expect the company to turn a profit this year. Moreover, the company's revenue over the last twelve months as of Q1 2024 stands at $0.29 million, showing a steep decline of 82.59%.
Despite these challenging financial metrics, Viridian exhibits some strengths in its balance sheet. InvestingPro Tips highlight that the company holds more cash than debt, providing a degree of financial stability. Additionally, liquid assets exceed short-term obligations, which may offer some reassurance to investors regarding the company's short-term financial health. However, it is also important to note that the company has been quickly burning through cash and suffers from weak gross profit margins, which could impact its long-term sustainability.
The market has responded to these mixed signals, with Viridian's stock price falling significantly over the last three months. Yet, there may be a silver lining—6 analysts have revised their earnings upwards for the upcoming period, which could suggest a more optimistic future outlook. For those interested in a deeper analysis, InvestingPro offers additional tips on Viridian Therapeutics; using the coupon code PRONEWS24 can secure an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.